Other Clinical Trial - PRP vs Bevacizumab for PDR Treatment

Status Completed

Clinical Trial Summary

Protocol S by DRCR.net has shown that receive Ranibizumab as anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred panretinal photocoagulation (PRP) are non-inferior to those in eyes that receive standard prompt PRP therapy, however with some visual functional benefits and less complications with Ranibizumab arm.

Applying Protocol S in real world scenario may add cost burden to the patient as patients need about 7 injections per year which will cost the patient about 7000 US dollars a year as minimum The primary objective of this protocol is to determine the visual acuity outcomes at 1 year in eyes with proliferative diabetic retinopathy (PDR) using Bevacizumab 1.25 mg instead of Ranbizumab to lower the cost burden

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Retinal Diseases

Clinical Trial Details

NCT number	NCT02705274
Study type	Interventional
Source	Marashi Eye Clinic
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	February 2016
Completion date	May 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01921192` - Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy	Phase 4
Recruiting	`NCT01044875` - Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy	N/A
Active, not recruiting	`NCT00993525` - Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)	Phase 1/Phase 2
Completed	`NCT01307072` - Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy	N/A
Completed	`NCT01758757` - Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy	N/A
Withdrawn	`NCT00600236` - HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population	Phase 3
Completed	`NCT05414149` - Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy	N/A
Completed	`NCT05408416` - Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR	N/A
Not yet recruiting	`NCT04464694` - Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema	Phase 4
Not yet recruiting	`NCT03633266` - Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy	N/A
Completed	`NCT03490318` - Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
Completed	`NCT01627977` - Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy	Phase 3
Completed	`NCT00776763` - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab	Phase 2
Terminated	`NCT00563043` - Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment	Phase 4
Completed	`NCT00682240` - Morphological and Functional Retinal Changes Following Retinal Photocoagulation	Phase 4
Terminated	`NCT00563628` - Changes in Macular Thickness After Patterns Scan Laser	Phase 4
Completed	`NCT00446381` - Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)	N/A
Completed	`NCT02879422` - Genetic Markers and Proliferative Diabetic Retinopathy	N/A
Enrolling by invitation	`NCT02911311` - Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy	N/A
Recruiting	`NCT05514925` - Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy	Phase 4